CRISPR genome editing technology
32353252 ä. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
32071427 2020. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses
Microbiome as target, Probiotics
32356654 ä. Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles
32339473 ä. Probiotics and COVID-19: one size does not fit all
32255312 2020. A possible probiotic (S salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2
32374010 2020. Are probiotics effective adjuvant therapeutic choice in patients with COVID-19?
32374009 2020. Potential mechanisms by which the oxygen-ozone (O2-O3) therapy could contribute to the treatment against the coronavirus COVID-19
32437014 2020. A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19.
32384798 2020. Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19.
Hemoglobin O2 affinity
32360083 ä. Modulation of Hb-O2 affinity to improve hypoxemia in COVID-19 patients
32318324 ä. Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival
32251365 ä. Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy
Autophagy and other vacuoles
32226290 2020. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19
|32402856 2020. Could an endo-lysosomal ion channel be the Achilles heel of SARS-CoV2?|
32285908 2020. Chloroquine and bafilomycin A mimic lysosomal storage disorders and impair mTORC1 signalling
32305009 ä. Investigating hypothiocyanite against SARS-CoV-2
dehydration of mucous glycans
32373322 ä. Fighting COVID-19 with water
32324533 2020. Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients
32344312 2020. Potential effect of natural and anabolizan steroids in elderly patient with COVID-19
32353355 ä. Testosterone, a key hormone in the context of COVID-19 pandemic
32490931 2020. 17beta-Estradiol, a potential ally to alleviate SARS-CoV-2 infection.
32297843 2020. Oligonucleotides and the COVID-19 Pandemic: A Perspective
32297156 ä. Computational Identification of Small Interfering RNA Targets in SARS-CoV-2
16433589 2006. (+)Antiviral applications of RNAi for coronavirus
32362826 2020. Editorial: New Advances in RNA Targeting
20956884 2010. (+)Small Interfering RNA Effectively Inhibits the Expression of SARS Coronavirus Membrane Gene at Two Novel Targeting Sites
32315229 2020. COVID-19 and the CRISPR Community Response
32366131 2020. Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine
|32208449 2020. BRD4 inhibition exerts anti-viral activity through DNA damage-dependent innate immune responses|
32335456 2020. The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?
Cell entry modulators
32191676 2020. Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?
32275178 2020. Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease
32352615 2020. Povidone-iodine gargle as a prophylactic intervention to interrupt the transmission of SARS-CoV-2
32326426 2020. COVID-19: A Recommendation to Examine the Effect of Mouthrinses with beta-Cyclodextrin Combined with Citrox in Preventing Infection and Progression
32367847 2020. Nasopharyngeal wash in preventing and treating upper respiratory tract infections: Could it prevent COVID-19?
32234338 ä. Using psychoneuroimmunity against COVID-19
32507360 2020. Delirium, sleep, COVID-19 and melatonin.
32504754 2020. Is melatonin deficiency a unifying pathomechanism of high risk patients with COVID-19? trained immunity
32437659 2020. Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection
32380052 2020. Granulocyte-targeted therapies for airway diseases